Warning: The NCBI web site requires JavaScript to function. more...
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.
Wang X, Wang JP, Maughan MF, Lachman LB.
Breast Cancer Res. 2005;7(1):R145-55. Epub 2004 Nov 29.
Related citations
Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB.
Breast Cancer Res. 2005;7(5):R580-8. Epub 2005 May 23.
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.
Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 7.
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM, Johnston RE, Serody JS.
Vaccine. 2007 Sep 4;25(36):6604-12. Epub 2007 Jul 17.
Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, Elmishad AG, Kast WM, Smith LR.
Cancer Res. 2001 Nov 1;61(21):7861-7.
Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S, Chan T, Sami A, El-Gayed A, Xiang J.
Cancer Gene Ther. 2008 Oct;15(10):655-66. Epub 2008 Apr 18.
DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB, Rao XM, Kremer RH, Ozpolat B, Kiriakova G, Price JE.
Cancer Gene Ther. 2001 Apr;8(4):259-68.
VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model.
Laust AK, Sur BW, Wang K, Hubby B, Smith JF, Nelson EL.
Breast Cancer Res Treat. 2007 Dec;106(3):371-82. Epub 2007 Mar 10.
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.
Ann Surg Oncol. 2006 Aug;13(8):1085-98. Epub 2006 Jul 24.
p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
Cancer Res. 2006 May 1;66(9):4672-80.
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.
White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE.
J Virol. 2007 Oct;81(19):10329-39. Epub 2007 Jul 25.
HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T, Sami A, El-Gayed A, Guo X, Xiang J.
Gene Ther. 2006 Oct;13(19):1391-402. Epub 2006 May 25.
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL, Disis ML.
Clin Breast Cancer. 2001 Apr;2(1):73-9. Review.
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD.
PLoS One. 2010 Sep 10;5(9). pii: e12670.
Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.
Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A.
Cancer Gene Ther. 2011 Jan;18(1):53-62. Epub 2010 Aug 20.
Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors.
Andreasson K, Tegerstedt K, Eriksson M, Curcio C, Cavallo F, Forni G, Dalianis T, Ramqvist T.
Int J Cancer. 2009 Jan 1;124(1):150-6.
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA, Vellon L, Lupu R.
Ann Oncol. 2005 Aug;16(8):1253-67. Epub 2005 May 3.
Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.
Cecil C, West A, Collier M, Jurgens C, Madden V, Whitmore A, Johnston R, Moore DT, Swanstrom R, Davis NL.
Virology. 2007 Jun 5;362(2):362-73. Epub 2007 Feb 1.
Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R.
Int J Oncol. 2007 Feb;30(2):381-92.
Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
Clin Cancer Res. 2009 Jul 15;15(14):4612-21. Epub 2009 Jul 7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on